NBTXR3 activated by Brachytherapy & IMRT not checked

Nanobiotix

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment”In the company’s words, NCT02805894 on ClinicalTrials.gov
Tested for
Prostate Cancer
Main trialPhase 1/2
“This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT and the other group will receive a Brachytherapy boost and EBRT. Both groups will receive treatment with androgen deprivation. There will be 2 consecutive steps, a dose escalation and a subsequent dose expansion part.”In the company’s words, NCT02805894 on ClinicalTrials.gov
Other names
Hafnium Oxide nanoparticles

Other drugs for Prostate Cancer

All 193 drugs for Prostate Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Terminated 19 Mar 2020 NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow NBTXR3 activated by Brachytherapy & IMRT

Following is part of Solo: you see every change to NBTXR3 activated by Brachytherapy & IMRT the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in